Peptide Therapeutics Market: Statistics & Market Size (2026)

Global peptide therapeutics market: roughly $50B-$141B in 2025-26 depending on scope, ~8% annual growth. Every estimate, GLP-1 sale, and FDA stat, fully sourced.

Key Peptide Therapy Statistics (2026)

The numbers below are the most-cited peptide market statistics for 2026, each one current, attributed to a named firm or company report, and written to stand on its own.

The one number, and why it has a range

Ask "how big is the peptide therapeutics market?" and the honest answer is a range, not a point. For 2025 and 2026, credible firms land anywhere from about $50 billion to $141 billion, with the single most-cited figure, Grand View Research's $140.86 billion for 2025, sitting at the top of that band. The spread is almost threefold. It is not measurement error. It comes down to one decision each firm makes about what counts as a peptide therapeutic, and we walk through that below so you can pick the number that fits your context and cite it with confidence.

Growth is the part everyone agrees on. Whichever base they start from, analysts forecast the peptide therapeutics market to expand at roughly 6% to 11% a year through the early 2030s. That pace doubles the market inside a decade, and the engine behind it is no mystery: GLP-1 receptor agonists for diabetes and obesity.

How big is the peptide therapeutics market?

Depending on scope, the global peptide therapeutics market is worth between about $50 billion and $141 billion in 2025-2026. Here is what the major research firms actually publish, side by side. Every figure is the firm's own most recent estimate, linked to the source.

Note: base years range from 2024 to 2026 and forecast horizons from 2031 to 2036, so the headline figures are not strictly like-for-like. CAGR periods follow each firm's own report.

Why the estimates disagree by almost 3x

The firms are not measuring different worlds. They are drawing the boundary in different places. Two questions decide which camp a forecast lands in.

First, do you count the GLP-1 metabolic blockbusters? Ozempic, Wegovy, Mounjaro, and Zepbound are peptides by chemistry. Folding their combined sales into the market lifts the 2025 total toward $130-141 billion, which is where Grand View Research and Fortune Business Insights sit. Leave the largest GLP-1 franchises out, or treat them as a separate metabolic category, and the "core" peptide therapeutics market falls back near $50 billion, where Precedence Research, Mordor Intelligence, Global Market Insights, and Future Market Insights cluster. Roots Analysis lands in the middle at $88.7 billion.

Second, do you count insulins and older peptide hormones? Some models include the full legacy peptide pharmacopeia; others focus on modern innovator drugs. That choice moves the base by tens of billions on its own.

The practical guidance for anyone citing a number: if you mean the broad market including the GLP-1 obesity and diabetes giants, use roughly $130-141 billion (2025). If you mean the core peptide therapeutics market excluding those franchises, use roughly $50 billion (2025-2026). State which one you mean, and the figure will hold up.

A short market-size timeline

The trend matters more than any single year. Tracking the narrower-scope definition over time shows the climb clearly: the peptide market was estimated near $41.4 billion in 2023, about $46.4 billion in 2024 (Global Market Insights), and roughly $50-53 billion across 2025-2026. The broad-scope definition, carried up by GLP-1 sales, reached about $132-141 billion in 2025. Two scopes, one direction. The line goes up either way, and it steepens right when semaglutide and tirzepatide volumes take off.

Market by segment: type, application, route, and synthesis

Branded, innovator peptides dominate value, injectables dominate delivery, and metabolic disease dominates demand. The segment splits are where the GLP-1 story shows up in the data.

Market by region

North America is the largest peptide therapeutics market, and Asia-Pacific is the fastest-growing. The regional share estimates vary with the same scope differences as the headline numbers, but the ranking is consistent across firms.

North America's share of the global market is estimated between about 38% and 62%, with Precedence Research at 45.96%, Grand View Research at 61.99%, and Mordor Intelligence at 38.34% for 2025. The gap reflects how much GLP-1 revenue, heavily concentrated in the United States, each firm pulls into the total. Asia-Pacific is the consensus growth leader, forecast to expand faster than any other region, with estimates running from about 6.2% (Precedence Research) to 12.8% (Mordor Intelligence) a year. Europe remains a solid second market by size.

GLP-1 and the flagship peptide drugs

Two GLP-1 molecules, semaglutide and tirzepatide, generated roughly $70 billion in combined 2025 sales. No other class comes close, and these drugs are the reason the broad-scope market sits where it does.

Eli Lilly's tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, reached $36.5 billion in 2025, about 56% of the company's total revenue. Mounjaro alone brought in $22.97 billion (up 99% year over year) and Zepbound $13.54 billion (up 175%), per Eli Lilly's full-year 2025 results.

Novo Nordisk's semaglutide franchise is the other half of the story. In 2025, Ozempic generated DKK 127.1 billion (about $18.7 billion), Wegovy DKK 79.1 billion (about $11.6 billion), and the oral version Rybelsus DKK 22.1 billion (about $3.3 billion), per the Novo Nordisk Annual Report 2025. That is roughly $33-34 billion for semaglutide, on top of Lilly's $36.5 billion for tirzepatide.

Put the two franchises together and you reach about $70 billion from a single drug class in one year. For scale, that figure exceeds the entire narrow-scope peptide therapeutics market and equals roughly half of the broad-scope estimate. Novo Nordisk holds a 59.6% branded volume share of the global GLP-1 obesity market, and Global Market Insights estimated Novo's overall peptide market share above 17% in 2024, with the top five players (Novo Nordisk, Eli Lilly, Bristol-Myers Squibb, Ferring, and Merck) holding about 60% combined.

This is the same wave that has reshaped consumer demand for GLP-1 weight loss drugs and the broader category of peptides studied for fat loss, and it is why peptides are the most-watched drug class in pharma right now.

FDA-approved peptide drugs and the pipeline

Around 120 peptide drugs are on the market worldwide, with more than 80 holding regulatory approval and over 170 in active clinical trials. Peptides sit between small molecules and biologics, offering high target specificity with lower immunogenicity, and regulators have steadily added to the approved list.

A 2025 analysis in Pharmaceuticals counted around 120 peptide drugs on the market and 34 FDA peptide approvals between 2016 and 2024. In 2024, the FDA approved 50 novel drugs in total, of which two were new peptides. More than 170 peptide candidates are in active clinical development, and the next wave of obesity and metabolic candidates, including retatrutide, is already in late-stage trials. For a fuller picture of the science behind these molecules, see our guide to what peptides are used for.

A note on the count: published figures range from "more than 80 approved" to "around 120 on the market" because some tallies count only FDA approvals while others count drugs marketed anywhere in the world, and a few approved peptides have since been withdrawn. Either way, the pipeline is deeper than the approved list, which is what keeps the growth forecasts high.

Real-world adoption: how the market reaches people

18% of US adults said they had used a GLP-1 drug as of late 2025, up from 12% in 2024. Market size is one lens; actual use is another, and the adoption curve has bent sharply upward.

In its November 2025 health tracking poll, KFF found that nearly one in five adults (18%) had ever used a GLP-1 agonist, with 12% currently taking one. That is double the 6% who were current users in KFF's May 2024 survey. Use runs highest among people with diabetes (45% currently using), adults aged 50 to 64 (22%), and women (15% versus 9% for men). Among adults not yet taking a GLP-1, about 22% said they would be interested in one for weight loss, which points to further demand ahead even as affordability remains a barrier.

What is driving growth

The market's growth is concentrated, not broad-based, and four forces explain most of it.

Headwinds are real too: lower realized prices, US pricing reform, and looming patent expirations on the semaglutide molecule in some markets are all expected to slow reported growth in 2026, even as patient volumes keep climbing.

Frequently asked questions

How big is the peptide therapeutics market?

The global peptide therapeutics market is worth roughly $50 billion to $141 billion in 2025-2026, depending on scope. The most-cited single figure is Grand View Research's $140.86 billion for 2025, which includes the GLP-1 metabolic blockbusters. Estimates that exclude those franchises cluster near $50 billion.

Is the peptide market growing?

Yes. Every major firm forecasts growth, with annual rates clustered between 6% and 11%. At that pace the market roughly doubles within a decade. GLP-1 receptor agonists for diabetes and obesity are the primary engine.

How many peptide drugs are FDA-approved?

More than 80 peptide drugs hold regulatory approval, and around 120 are on the market worldwide as of 2025. The FDA approved two new peptides in 2024, part of 34 peptide approvals between 2016 and 2024. Over 170 more peptides are in active clinical trials.

What is the fastest-growing peptide segment?

By application, metabolic and obesity peptides are growing fastest, led by GLP-1 drugs. By route, oral peptides are the fastest-growing delivery format off a small base. By region, Asia-Pacific is the fastest-growing geography.

What is the best-selling peptide drug?

By 2025 revenue, tirzepatide (sold as Mounjaro and Zepbound) led at $36.5 billion, ahead of Novo Nordisk's Ozempic at about $18.7 billion. Both are GLP-1 receptor agonist peptides.

Why do peptide market estimates vary so much?

The main reason is scope. Firms differ on whether to count the GLP-1 obesity and diabetes giants and older insulins as peptide therapeutics. Including them pushes the 2025 market toward $130-141 billion; excluding them brings it near $50 billion.

Sources and methodology

All figures were gathered and verified on June 14, 2026. Where a source published a figure older than about two years, we replaced it with the firm's most recent estimate. Market-size figures are each firm's own published number; where currencies were reported in Danish kroner, USD conversions are approximate at about 6.8 DKK per USD and labeled as such. Company drug-sales figures come directly from 2025 annual reports.

Figures are presented as published by each source and are not investment advice. Market-research estimates reflect each firm's methodology and scope, which differ; we report them side by side rather than averaging across incompatible definitions.

How to cite this report

Peptide Mind Research Team. (2026). Peptide Therapeutics Market: Statistics & Market Size (2026): The Complete Data Report. Peptide Mind. https://peptidemind.com/peptide-therapeutics-market-statistics

You are welcome to cite or quote any statistic on this page with attribution and a link back to Peptide Mind.